Day: March 26, 2026

Golar LNG Limited advises that its 2026 Annual General Meeting will be held on Tuesday May 19, 2026.  The record date for voting at the Annual General Meeting is set to April 6, 2026. A copy of the notice, agenda and associated material will be distributed to shareholders by normal distribution methods prior to the meeting and will also be made available on the Company’s website at www.golarlng.com Golar LNG LimitedHamilton, BermudaMarch 26, 2026 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

ToNasdaq Copenhagen A/S   Executive ManagementBernstorffsgade 401577 København Vwww.rd.dk Telephone +45 7012 5300 26 March 2026Company announcement number 25/2026 Fixing of coupon rate effective from 1 April 2026With effect from 1 April 2026, the coupon rate of the following bonds financing RD Euribor3®, RD Stibor3®, RD Stibor3® Green, RD Nibor3®, RD Cibor6® (RO), FlexGaranti® and RenteDyk® will be adjusted.          Please find the data in the attached file.The Executive Management Any additional questions should be addressed to Chief Analyst Hella Gebhardt Rønnebæk, Phone +45 45 13 20 68.AttachmentsNr. 25_Fastsaettelse af kuponrente pr. 01.04.2026_ukBilag til selskabsmeddelelse nr. 25-2026_uk

MIAMI, FL , March 26, 2026 (GLOBE NEWSWIRE) — RenX Enterprises Corp. “RenX” (NASDAQ: RENX), a  biomass recycling, logistics, and real estate company, today announced that it has received written confirmation from MTDH Germany GmbH (“Microtec”) that the  UTM 1200 Turbo Mill ordered by the Company has been completed at the Microtec manufacturing facility and is being prepared for shipment from Germany to RenX’s Myakka City, Florida facility. Delivery to the site is expected in April 2026, as the Company works to finalize site preparation and coordinate installation logistics. The Microtec UTM 1200 is the primary size-reduction component of the Microtec milling system, a 12-step engineered processing circuit designed to process up to 10 tons per hour of woody biomass screened from compost and produce three specification-defined particle...

HOUSTON and TORRANCE, Calif., March 26, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), the advanced battery intelligence solution for autonomous platforms, digital infrastructure, e-mobility, and spaceflight applications, today announces a strategic co-development collaboration with Robinson Helicopter Company (RHC), the world’s leading manufacturer of civil helicopters, to develop a next-generation, high-performance battery system for an eR66 battery-electric helicopter demonstrator.Under the agreement, KULR is expected to serve as a developer of the advanced battery system for the eR66 platform. The Company intends to design and integrate a lightweight, high-performance battery architecture using KULR’s proprietary battery safety technologies...

HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company’s largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein’s prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further underscores his continued support in Pluri’s strategy, underlying asset base, and long-term value creation opportunity. “Making an additional...

– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied – Ongoing Clinical Data Continues to Support Development of QRX003 as a Treatment for Peeling Skin Syndrome with Study Being Expanded to 6 Subjects – Proprietary Rapamycin Topical Platforms Achieve Target Loadings;...

Two-year master task agreement expands Perma-Fix’s nuclear services project portfolio and reinforces its long-standing relationship supporting work at LLNL ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced it has been awarded a two-year master task agreement valued at approximately $24 million by Lawrence Livermore National Security, LLC (“LLNS”) for demolition and disposal at Lawrence Livermore National Laboratory (“LLNL”) in Livermore, California. Under the agreement, Perma-Fix will provide demolition, excavation, and waste management services to support the safe disposition of these facilities as part of site efforts aligned with LLNL’s national security mission. The project is expected to draw on Perma-Fix’s technical expertise in complex radiological...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the Company’s intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhanced formulation properties and potential efficacy benefits, creating an opportunity to extend the asset’s lifecycle and broaden its clinical and...